A Message from Our CEO

We continue to drive significant progress on our sustainability agenda, including:

• Reducing greenhouse gas emissions in our operations by more than 20% between 2020 and 2022, while our business has grown significantly.

• Outperforming the biotech and pharmaceutical industry average with an A- score for climate and water submissions from CDP in 2022.

• Continuing to make progress in the diversity of our workforce, with women representing 49% of management positions, and minority group members increasing to 25% in 2022.

• Increasing the number of patients reached in our Global Health efforts to 13 million.

• Meaningful progress expanding the access and affordability of our medicines. In the U.S., we’ve been working for years to close gaps in the healthcare system and improve access to insulin. With the aggressive actions we’re taking this year, we’re making it even easier for people to get this life-saving medicine: capping out-of-pocket costs at $35 or less a month for more patients who use Lilly insulin; introducing a $25 authorized generic of Humalog; and cutting prices 70 percent on our most commonly-prescribed insulins.

As our impact on people and communities around the world grows, sustainability remains central to delivering on our purpose and driving business results. Thank you for your interest in our ESG strategy and progress.

Regards,

David A. Ricks

Chair and CEO

My signature above affirms our company’s ongoing commitment and our intent to support and advance the United Nations Global Compact’s ten universally accepted principles in the areas of human rights, labor, environment and anti-corruption, in addition to the United Nations Sustainable Development Goals.

See important information about our ESG report.